Hong Kong – October 08, 2026 -- Sisram Medical Ltd (1696.HK) has announced a share repurchase plan to buy back up to 1% of its total issued shares on the open market, citing confidence in its long-term growth trajectory.
Buyback plan allows cancellation or treasury retention of shares
Under the existing share repurchase mandate, repurchased shares may either be cancelled or held as treasury shares depending on future capital management needs. The plan will be executed subject to market conditions, with the Board stating it will balance business development priorities, strategic investment needs and financial flexibility.
First-half 2026 revenue climbs 3.6% to US$171.4 million
Sisram reported H1 2026 revenue of US$171.4 million, up 3.6% year-on-year. International markets excluding North America drove growth, rising 16.7% YoY to US$127.0 million, with APAC generating US$78.4 million, a 19.1% YoY increase.
Injectables revenue surges 54.2% to become second growth engine
The injectables segment posted revenue of US$22.2 million, up 54.2% YoY, now accounting for 12.9% of total revenue. The commercialization of DAXXIFY in mainland China progressed steadily, while Profhilo and Hallura expanded their market presence. In the EBD business, flagship platforms Alma Harmony and Hybrid maintained market traction alongside new product rollouts across APAC and localization efforts in China.
Company anchors strategy on three global hubs in Israel, US and China
Sisram said it will deepen integration of R&D, global commercial operations and localized capabilities through its strategic hubs, while accelerating registration and commercialization of key products in major markets. The Company also plans to explore partnerships that create synergies within its broader wellness ecosystem.
"We are launching this share repurchase after a comprehensive assessment of Sisram's business performance, financial position and market conditions, reflecting our confidence in the Company's long-term prospects," said Jiahong Li, Co-CEO and CFO of Sisram.